Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Protein or biologic · Protein or protein analogue
Detailed molecular class: Glycoprotein hormone
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Erythropoietin-receptor signaling stimulates erythropoiesis.
Evidence and critical reading
Reported scientific and empirical uses
Hematologic context
Catalog EPO is incomplete identity; distinguish epoetin, other variants and authorized product.
Human evidence
Approved epoetin alfa products have restricted anemia and surgical indications.
Preclinical evidence
No extrapolation from anemia treatment to athletic enhancement.
Critical reading and limitations
Treating anemia in a defined indication does not establish safe performance/longevity use.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: Epogen label verified; a catalog label EPO does not identify that product.
Adverse effects and unknowns
Serious thrombotic/cardiovascular risks; contraindications include uncontrolled hypertension, antibody-mediated pure red-cell aplasia after erythropoietin and serious allergy.
Thrombosis, cardiovascular events and hypertension are label risks; IU cannot be generically converted to mg.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
epoetin · 976 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT05564390 · MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Registry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07855458 · ESA Hyporesponsiveness in Hemodialysis PatientsRegistry status: Not yet recruitingLast update posted: October 2, 2026Query verification: October 16, 2026
NCT07517562 · The Effects of Acute Erythropoietin on Hepcidin and Dietary Iron Absorption Following Military-relevant Exercise in Energy Deficit: Pilot StudyRegistry status: Active, not recruitingLast update posted: October 2, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REG-EPO
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026